DARPin

Molecular Partners will present pipeline updates and its 2025 outlook at the J.P. Morgan Healthcare Conference. CEO Patrick Amstutz will discuss advancements in their novel DARPin drug technology, focusing on oncology. The presentation, webcast live, is expected to detail clinical progress, strategic direction, and financial projections for the coming year, offering insights into the company’s innovative therapeutic approach and market potential.

.Molecular Partners (NASDAQ:MOLN) presented updated Phase 1/2a data for its tetra‑specific T‑cell engager MP0533 in relapsed/refractory AML at ASH 2025. Of 54 patients treated, 8 of 48 evaluable patients responded, including five composite complete responses and three morphologic leukemia‑free states. Densified, higher‑frequency dosing (cohorts 8‑9) was well tolerated and yielded markedly higher serum exposure, with responses concentrated in patients whose baseline marrow blasts were below 20 %. One cohort‑8 patient remains in remission for over a year; cohort 10 results are expected in 2026.